 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | BPI-361175 / Betta Pharma
Trial initiation date, Metastases: BPI-361175 Tablets in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Oct 18, 2022
P1/2, N=30, Not yet recruiting, Sponsor: Xcovery Holding Company, LLC
Initiation date: Jul 2022 --> Jul 2023
- || BPI-361175 / Betta Pharma
New P1/2 trial, Metastases: BPI-361175 Tablets in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - May 26, 2022
P1/2, N=30, Not yet recruiting, Sponsor: Xcovery Holding Company, LLC
- |||| BPI-361175 / Betta Pharma
New P1/2 trial, Metastases: A Phase 1/2 Study of BPI-361175 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Apr 14, 2022
P1/2, N=90, Recruiting, Sponsor: Betta Pharmaceuticals Co., Ltd.
- BPI-361175 / Betta Pharma
BPI-361175, a 4th generation EGFR-TKI for the treatment of non-small cell lung cancer (NSCLC) (E-Poster Website) - Mar 9, 2022 - Abstract #AACR2022AACR_6923;
In conclusion, BPI-361175 is a potent, selective, and orally bioavailable 4th generation EGFR-TKI which can potentially be used to treat NSCLC resistant mutations as well as at front line. Phase I clinical trial of BPI-361175 is enrolling patients in China, and US Phase I trial is expected to initiate in Q1 2022.